Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M

Trial Profile

Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Gadobutrol (Primary)
  • Indications Vascular disorders
  • Focus Pharmacokinetics
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 14 Jul 2015 According to a Bayer HealthCare media release, gadobutrol (Gadovist) has received approval for diagnostic use in pediatric patients less than 2 years of age in the European Union. The approval was based on results from this trial.
    • 22 Jan 2015 New trial record
    • 05 Jan 2015 According to the media release, the US FDA has approved gadobutrol for use with magnetic resonance imaging in pediatric patients less than 2 years of age, including term neonates. Based on the data from this trial, priority review was granted by the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top